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Polymyxin-resistant mutants of Escherichia coli and
Salmonella typhimurium accumulate a novel minor
lipid that can donate 4-amino-4-deoxy-L-arabinose units
(L-Ara4N) to lipid A. We now report the purification of
this lipid from a pssⴚ pmrAC mutant of E. coli and assign
its structure as undecaprenyl phosphate-␣-L-Ara4N. Approximately 0.2 mg of homogeneous material was isolated from an 8-liter culture by solvent extraction, followed by chromatography on DEAE-cellulose, C18
reverse phase resin, and silicic acid. Matrix-assisted laser desorption ionization/time of flight mass spectrometry in the negative mode yielded a single species [M ⴚ
H]ⴚ at m/z 977.5, consistent with undecaprenyl phosphate-␣-L-Ara4N (Mr ⴝ 978.41). 31P NMR spectroscopy
showed a single phosphorus atom at ⴚ0.44 ppm characteristic of a phosphodiester linkage. Selective inverse
decoupling difference spectroscopy demonstrated that
the undecaprenyl phosphate group is attached to the
anomeric carbon of the L-Ara4N unit. One- and twodimensional 1H NMR studies confirmed the presence of
a polyisoprene chain and a sugar moiety with chemical
shifts and coupling constants expected for an equatorially substituted arabinopyranoside. Heteronuclear multiple-quantum coherence spectroscopy analysis demonstrated that a nitrogen atom is attached to C-4 of the
sugar residue. The purified donor supports in vitro conversion of lipid IVA to lipid IIA, which is substituted with
a single L-Ara4N moiety. The identification of undecaprenyl phosphate-␣-L-Ara4N implies that L-Ara4N transfer to lipid A occurs in the periplasm of polymyxinresistant strains, and establishes a new enzymatic
pathway by which Gram-negative bacteria acquire antibiotic resistance.

Polyisoprene-linked sugars function as donor substrates for
many types of glycosyltransferases (1). In eubacteria, undecaprenyl moieties (1, 2) serve as lipid carriers for sugar residues
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that are transferred to acceptors located outside of the cytoplasm, where sugar nucleotides are not available. Undecaprenyl diphosphate-sugars (generally oligosaccharides) are precursors for polymerization of O-antigen (3– 6), enterobacterial
common antigen (7, 8), and peptidoglycan (1, 9 –11). Undecaprenyl phosphate-sugars (typically monosaccharides) are
thought to be donors for processes that include bacteriophagemediated O-antigen conversion (12, 13), glycosylation of teichoic acids (14 –17), and biosynthesis of mycobacterial lipoglycans (18 –21). In eucaryotic cells, the structurally related
dolichyl phosphate-sugars and dolichyl diphosphate-sugars (1,
22–24) play important roles in various stages of protein glycosylation and in the assembly of phosphatidylinositol-linked
glycans.
As demonstrated in the preceding article (25), a membranebound donor, proposed to be undecaprenyl phosphate-␣-LAra4N1 (Fig. 1)2 based upon bioinformatic considerations (26,
27), is required for the modification of lipid A with 4-amino-4deoxy-L-arabinose (L-Ara4N) units in polymyxin-resistant mutants of Escherichia coli and Salmonella typhimurium. A novel
L-Ara4N transferase, encoded by arnT (previously designated
orf5 or pmrK) (28, 29), catalyzes L-Ara4N transfer to lipid
A-like molecules in vitro when membranes of polymyxin-resistant mutants are employed as the source of the L-Ara4N donor
(25). The formation of L-Ara4N and its transfer to lipid A are
induced by activation of the transcription factor PmrA, which
may occur by mutation (30 –32), by activation of PhoP (33, 34),
or by exposure of cells to mildly acidic pH, ferric ions, or
metavanadate (26, 35, 36). Attachment of the positively
charged L-Ara4N moiety to lipid A is critical for resistance to
the antibiotic polymyxin and to certain cationic antimicrobial
peptides present inside phagocytic cells (37, 38).
We now report the purification and structural characterization of a novel, minor lipid that accumulates in polymyxinresistant mutants of E. coli and S. typhimurium. The purified
lipid functions as a donor of L-Ara4N residues in the ArnTcatalyzed modification of lipid A in vitro. MALDI/TOF mass
spectrometry and high resolution NMR spectroscopy strongly
1
The abbreviations used are: L-Ara4N, 4-amino-4-deoxy-L-arabinose;
pEtN, phosphoethanolamine; Mes, 2-[N-morpholino]ethanesulfonic
acid; Kdo, 3-deoxy-D-manno-octulosonic acid; MALDI/TOF mass spectrometry, matrix-assisted laser desorption ionization/time of flight
mass spectrometry; HMQC, heteronuclear multiple-quantum coherence spectroscopy; HMBC, heteronuclear multiple-bond correlation
spectroscopy.
2
A systematic chemical name for undecaprenyl phosphate-␣-LAra4N would be undecaprenyl 4-amino-4-deoxy-␣-L-arabinopyranosyl
phosphate.
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TABLE I
Bacterial strains and plasmids
Strains and
plasmids

S. typhimurium
ATCC 14028s
CS022
CS015
CS330
JSG435
JSG421
E. coli
W3110
WD101
WD102
AKK211
AD90
WD901
BLR(DE3)
NovaBlue(DE3)
Plasmids
pET21a
pArnTEc
pArnTSt
pDD72
pT7Blue-3
pWTD5
pWTD6
pLysS

Description

Source or Ref.

Wild type
pho-24 (PhoP-constitutive)
CSO22, phoP102⬋Tn10d-cam
CSO22, pagP⬋TnphoA
pmrA505 zjd⬋Tn10d-cam (PmrA-constitutive)
pmrA⬋Tn10d

ATCC
71
54
72
33
33

Wild type, F⫺, ⫺
W3110, pmrAC
zjd-2211⬋Tn10 derivative of WD101 (AKK211 donor)
⫺, relA1, spoT1, ilv-299, metB1, zjd⫺, 2211⬋Tn10, ampCp-1, mcrB⫺, creC510
pss93⬋kan nadB⫹
pmrACzjd-2211⬋Tn10 derivative of AD90 (WD102 donor)
⌬(srl-recA)306⬋Tn10(DE3), Tetr
⌬(srl-recA)306⬋Tn10(DE3), Tetr

E. coli Genetic Stock Center, Yale University
This work
This work
E. coli Genetic Stock Center, Yale University
46
This work
Novagen
Novagen

Vector containing a T7lac promoter, Ampr
pET21a containing E. coli arnT
pET21a containing S. typhimurium arnT
pss⫹ covering plasmid with temperature-sensitive ori, Camr
Cloning vector, Kanr, Ampr
pT7Blue-3 containing pmrA/pmrB operon from wild-type W3110
pT7Blue-3 containing pmrA/pmrB operon from WD101
pACYC184 encoding T7 lysozyme, Camr

Novagen
25
25
46
Novagen
This work
This work
Novagen

support the proposal (25, 26) that the donor lipid has the
structure undecaprenyl phosphate-␣-L-Ara4N (Fig. 1). The unambiguous demonstration of an undecaprenyl-linked intermediate indicates that lipid A modification with the L-Ara4N
moiety occurs on the periplasmic surface of the inner membrane. Modification of lipid A with L-Ara4N units may provide
a new biochemical marker for lipid A flip-flop (39) across the
inner membrane.
EXPERIMENTAL PROCEDURES

Materials—32Pi and [␥-32P]ATP were obtained from PerkinElmer
Life Sciences. Silica Gel 60 (0.25-mm) thin layer plates were purchased
from EM Separation Technologies. Tryptone and yeast extract were
from Difco. Triton X-100 and bicinchoninic acid were from Pierce.
CDCl3, CD3OD, and D2O were purchased from Aldrich. All other chemicals were reagent-grade and were purchased from either Sigma or
Mallinckrodt.
Bacterial Strains—The strains used in the present study are described in Table I. Bacteria were usually grown at 37 °C in LB medium
(40), which contains 10 g of NaCl, 10 g of tryptone, and 5 g of yeast
extract per liter. When needed, cultures were supplemented with 100
g/ml ampicillin, 12 g/ml tetracycline, 30 g/ml chloramphenicol, or
30 g/ml kanamycin.
Preparation of Radiolabeled Substrates—[4⬘-32P]Lipid IVA was prepared using 100 Ci of [␥-32P]ATP, tetraacyldisaccharide 1-phosphate,
and membranes of E. coli cells overexpressing the 4⬘-kinase (LpxK), as
described previously (41– 43). To prepare Kdo2[4⬘-32P]lipid IVA, the
purified E. coli Kdo transferase (KdtA) was used in tandem with LpxK
(42, 43).
Preparation of Cell-free Extracts and Membranes—Typically, 100-ml
cultures of bacteria were grown to A600 ⫽ 1.0 at 37 °C and harvested by
centrifugation at 7,000 ⫻ g for 15 min. All steps were carried out at
4 °C. Cell pellets were resuspended in 50 mM Hepes, pH 7.5, at a protein
concentration of 5–10 mg/ml, and broken by passage through a French
press at 18,000 pounds/square inch. The crude extract was cleared by
centrifugation at 7,000 ⫻ g for 15 min. Membranes were prepared by
ultracentrifugation at 149,000 ⫻ g for 60 min, followed by resuspension
and a second ultracentrifugation step to remove all cytosolic components. The final membrane pellet was resuspended in 50 mM Hepes, pH
7.5, at a protein concentration of 5–10 mg/ml. The supernatant from the
first 149,000 ⫻ g centrifugation step was subjected to a second ultracentrifugation to remove residual membrane particles. All samples
were stored as aliquots at ⫺80 °C. Protein concentrations were determined with bicinchoninic acid (44) using bovine serum albumin as the
standard.
L-Ara4N Transferase (ArnT) Assay Conditions—The L-Ara4N transferase (ArnT) was assayed under optimized conditions in a 10-l reac-

tion mixture containing 50 mM Mes, pH 6.5, 0.2% Triton X-100, and 10
M of [4⬘-32P]lipid IVA (20,000 cpm/nmol) (25). Reactions were incubated at 30 °C at the indicated protein concentration and times and
were stopped by spotting 5-l portions onto a Silica Gel 60 TLC plate.
The substrate and product(s) were separated by developing the plate
with chloroform, pyridine, 88% formic acid, water (50:50:16:5, v/v), and
quantified using a Molecular Dynamics PhosphorImager equipped with
ImageQuant software. ArnT-specific activity was calculated from the
percentage of substrate converted to product and expressed as nmol/
min/mg (25).
Construction of a Polymyxin-resistant Mutant of E. coli K-12—Wildtype E. coli K-12 cells (W3110) were treated with 50 g/ml of the
mutagen N-methyl-N⬘-nitro-N-nitrosoguanidine (40). Approximately
107 cells were plated on LB agar containing 2 g/ml polymyxin B sulfate
(45). At this plating density, no growth of untreated cells was observed,
but with mutagenesis, polymyxin-resistant colonies were recovered at a
frequency of about 10⫺7. Several such colonies were purified twice on
LB agar containing 10 g/ml polymyxin B sulfate. The polymyxin
resistance phenotype of a representative isolate was moved into a
wild-type background (W3110) by P1vir transduction (40) by selecting
directly for polymyxin resistance at 10 g/ml on LB agar. To validate
the chromosomal location of the resistance gene in the transductant
(designated WD101), pmrA⫹ (basR) of E. coli was re-introduced into
WD101 by co-transduction with a linked Tn10 transposon at 37 °C,
using a P1vir lysate prepared on strain AKK211 (zjd-2211::Tn10). Several of the tetracycline-resistant transductants of WD101 (2 of 14)
generated in this manner had lost their polymyxin resistance, when
tested for growth of single colonies on LB agar containing 10 g/ml
polymyxin. This finding supports the idea that a mutation in pmrA is
responsible for the polymyxin resistance of WD101. To validate this
hypothesis, however, the pmrA and pmrB genes were amplified together by subjecting WD101 chromosomal DNA to polymerase chain
reaction, using Pfu DNA polymerase (Stratagene) according to the
manufacturer’s instructions. Both genes were sub-cloned into the vector
pT7Blue-3 (Novagen) using blunt end ligation at the EcoRV site. The
sequences of the forward and reverse primers were 5⬘-CAGGCTGCGGATGATATTCTGC-3⬘ and 5⬘-GTTTAACTACCGTGTTCAGCGTG-3⬘
respectively. The sequences of both genes were then determined to
locate mutation(s). Two amino acid residues were altered in PmrA of
WD101, demonstrating that this mutant is a likely pmrA constitutive
(pmrAC). No changes were found in the pmrB sequence.
Construction of a pmrAC Mutant of E. coli K12 Lacking Phosphatidylethanolamine—The presence of phosphatidylethanolamine interferes with the purification of undecaprenyl phosphate-L-Ara4N, since
both compounds are zwitterionic phospholipids. The E. coli K-12 strain
AD90 contains a kan insertion in the phospholipid biosynthetic gene
pss, resulting in the complete absence of phosphatidylethanolamine in
its membranes (46). AD90 cells harboring the temperature-sensitive
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FIG. 1. Structure of undecaprenyl
phosphate-␣-L-Ara4N and proposed
transfer of the L-Ara4N moiety to
core-lipid A by ArnT. The numbering
scheme for the undecaprenyl phosphate␣-L-Ara4N molecule is used for the NMR
analysis presented. The 4⬘- and 1-positions of lipid A are also indicated. The
active site of ArnT may be located on the
periplasmic surface of the inner membrane, given the involvement of an undecaprenyl phosphate-linked donor substrate (25). ArnT can also transfer the
L-Ara4N moiety to the 1-position of lipid A
(25) (not shown). In acceptor substrates
lacking the Kdo domain of the core, such
as lipid IVA (not shown), ArnT incorporates the L-Ara4N unit exclusively at the
1-position (25).

pss⫹ covering plasmid pDD72 grow normally at 30 °C on LB broth,
because normal amounts of phosphatidylethanolamine are synthesized
under these conditions (46). Growth of AD90 cured of its covering
plasmid after a shift to 42 °C is slow and requires supplementation of
the medium with 50 mM MgCl2 (46).
A tetracycline-resistant derivative of WD101 was selected by transducing zjd-2211::Tn10 from AKK211 into WD101, as described above,
and retrieving one of the polymyxin-resistant recombinants. The desired strain, WD102 (pmrAC zjd-2211::Tn10), was used to generate
another P1vir lysate with which the pmrAC allele could be transferred
into AD90/pDD72 by selecting for tetracycline resistance (12 g/ml) at
30 °C on LB agar, followed by screening of individual colonies for
polymyxin resistance at 10 g/ml as the unselected marker. A pmrAC
zjd-2211::Tn10 transductant of AD90/pDD72 was then cured of its
covering plasmid at 42 °C, as described previously (46), generating the
phosphatidylethanolamine-deficient strain WD901 (pss93::kan pmrAC
zjd-2211::Tn10). Like AD90, WD901 grew slowly on LB broth in the
presence of 50 mM MgCl2.
Extraction and Separation of Phospholipids from 32Pi-Labeled
Cells—Log phase cells were uniformly labeled with 5 Ci/ml of 32Pi in 5
ml of LB broth (or LB broth containing 50 mM MgCl2 when appropriate)
at a starting A600 of 0.05. Cells were grown in a rotary shaker at 37 or
30 °C as indicated and harvested when A600 reached ⬃1.0. The cells
were collected using a clinical centrifuge and washed with 5 ml of
phosphate-buffered saline, pH 7.4. To extract the 32P-labeled phospholipids, the cell pellet was resuspended in 3 ml of a single-phase Bligh/
Dyer mixture (47), consisting of chloroform/methanol/water (1:2:0.8,
v/v). After mixing and incubating for 60 min at room temperature, the
insoluble material was removed by centrifugation, and the supernatant
containing the 32P-labeled phospholipids was transferred to a clean

glass tube. The supernatant was converted to a two-phase Bligh/Dyer
system consisting of chloroform/methanol/water (2:2:1.8 v/v) by adding
1.2 ml of chloroform, 0.42 ml of methanol, and 1.17 ml of water. The
phases were separated by low speed centrifugation, and the lower phase
was removed. The sample was dried under a stream of N2 and redissolved in a small volume of chloroform/methanol (4:1, v/v). The
32
P-labeled phospholipids (100,000 cpm/lane) were separated on Silica
Gel 60 TLC plates in the solvent chloroform/methanol/water/NH4OH
(65:25:3.6:0.4, v/v). The plate was dried and exposed to a PhosphorImager screen overnight to visualize the 32P-containing bands.
Extraction of Lipid A from 32Pi-Labeled Cells—32Pi-Labeled cells
were grown, harvested, and extracted as described above with 3 ml of a
single phase Bligh/Dyer mixture. The insoluble residue, which contains
the 32P-labeled lipid A still covalently bound to lipopolysaccharide, was
recovered by centrifugation and subjected to hydrolysis at 100 °C in
12.5 mM sodium acetate buffer, pH 4.5, in the presence of 1% SDS to
cleave the Kdo-lipid A linkage (26, 48). The released 32P-labeled lipid A
species were extracted by the Bligh/Dyer method, and a portion was
spotted onto a Silica Gel 60 TLC plate (⬃10,000 cpm/lane) that was
developed in the solvent chloroform, pyridine, 88% formic acid, water
(50:50:16:5, v/v). The plate was dried and exposed to a PhosphorImager
screen overnight to visualize the 32P-lipid A species.
Large Scale Purification of the Putative Donor Lipid Undecaprenyl
Phosphate-L-Ara4N—A 200-ml culture of WD901 (pss93::kan pmrAC
zjd-2211::Tn10) was grown for ⬃36 h in LB broth containing 50 mM
MgCl2 to A600 of ⬃2.0. This culture was used to inoculate four 2-liter
cultures, each in a 6-liter Erlenmeyer flask, at a starting A600 of 0.05.
The cells were grown in a rotary shaker at 37 °C until A600 reached
⬃2.0, harvested by low speed centrifugation at 4 °C, and resuspended in
a total of 120 ml of phosphate-buffered saline, pH 7.4. The cell suspen-
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FIG. 2. Accumulation of a novel minor phospholipid in the polymyxinresistant E. coli mutant WD101. 32PLabeled lipid A species and phospholipids
were separated by TLC and visualized
with a PhosphorImager. The lipid A species were resolved using the solvent chloroform, pyridine, 88% formic acid, water
(50:50:16:5, v/v), and the phospholipids
were separated in chloroform/methanol/
water/NH4OH (65:25:3.6:0.4, v/v). The position of the putative L-Ara4N donor lipid,
seen only in the polymyxin-resistant mutant, is indicated.

sion was divided equally into six 125-ml Corex tubes. The content of
each tube was converted into a single phase Bligh/Dyer system by
addition of 25 ml of chloroform and 50 ml of methanol. After mixing and
60 min of incubation at room temperature, the insoluble material was
removed by centrifugation at 4000 ⫻ g for 15 min. The supernatants
were combined (570 ml final volume) and then divided equally into
eight clean 125-ml Corex centrifuge tubes. The content of each tube was
converted to a two-phase Bligh/Dyer system by adding 18.75 ml of
chloroform and 18.75 ml of water. After mixing, the phases were separated by centrifugation at 4000 ⫻ g for 15 min. The lower phases,
containing the phospholipids and the putative L-Ara4N donor lipid,
were pooled and dried by rotary evaporation.
The residue was dissolved in 60 ml of chloroform/methanol/water
(2:3:1 v/v) and subjected to a 30-s sonic irradiation in a bath apparatus.
The sample was then applied to a 20-ml DEAE-cellulose column in the
acetate form at room temperature, pre-equilibrated, and washed with
200 ml of chloroform/methanol/water (2:3:1 v/v) as described previously
(26, 49, 50). Fractions of 5 ml were collected. After the flow-through, the
column was washed with another 60 ml of chloroform/methanol/water
(2:3:1 v/v). The wash was followed by four separate 60-ml elution steps,
using the 2:3:1 system with the aqueous phases containing either 60,
120, 240, or 500 mM ammonium acetate in ascending order. For each
fraction emerging from the column, a 30-l sample was spotted onto a
TLC plate, and the lipids were separated using chloroform/methanol/
water/NH4OH (65:25:3.6:0.4, v/v). The presence or absence of the donor
lipid and other phospholipids was detected by charring with 10% sulfuric acid in ethanol. The putative donor lipid, which was initially
identified by its presence as a minor component among the lipids of a
pmrAC mutant and its absence in wild type, emerged in the flowthrough and the first 25 ml of the wash fractions, consistent with its net
charge of zero (Fig. 1). Fractions containing the donor lipid were pooled
(85 ml) and converted to a two-phase Bligh/Dyer system (see above).
The phases were separated by low speed centrifugation, and the lower
phase, which contained the donor lipid, was dried by rotary
evaporation.
Reverse phase C18 chromatography was used as the second step of
the purification. Solvent A, consisting of acetonitrile/water (1:1, v/v),
and solvent B, consisting of isopropanol/water (85:15, v/v), were used in
various ratios, and all solutions contained 10 mM tetra-butyl ammonium dihydrogen phosphate. A 4.0-ml C18 column was first equilibrated
using 40 ml of solvent A/B (1:1, v/v). The DEAE-cellulose purified donor
lipid fraction was dissolved in 12 ml of solvent A/B (1:1, v/v), subjected

to sonic irradiation for 60 s, and applied to the C18 column. The flowthrough was saved, and the column was washed stepwise with 40-ml
portions of A/B solvent mixtures as follows: A/B (1:1, v/v), A/B (1:2, v/v),
A/B (1:4, v/v), A/B (1:6, v/v), and A/B (1:10, v/v). All fractions were 4 ml,
and 30 l of each was spotted onto a TLC plate, after which the lipids
were separated in the system chloroform/methanol/water/NH4OH (65:
25:3.6:0.4, v/v). Lipids were detected by charring with 10% sulfuric acid
in ethanol. The donor lipid was found to elute in the A/B (1:10, v/v) step.
The fractions containing the putative donor lipid were pooled (⬃10 ml)
and dried immediately by rotary evaporation.
An additional fractionation on silicic acid was necessary to obtain
pure donor lipid. The above residue was dissolved in 10 ml of chloroform/methanol (95:5, v/v) and loaded onto a 1-ml acid-washed silicic
acid column (Bio-SilA from Bio-Rad), equilibrated in chloroform/methanol (95:5, v/v). After the flow-through, the column was washed with 5
ml of chloroform/methanol (95:5, v/v). The lipid was eluted using 5 ml of
chloroform/methanol (80:20, v/v), and the appropriate fractions (1 ml
each) were dried by rotary evaporation. To remove tetra-butyl ammonium dihydrogen phosphate carried over from the C18 column, the
solvent was converted into a two-phase Bligh/Dyer system (as described
above). The lower phase, containing the donor lipid, was washed 3 times
with fresh upper phase. Although a small amount of residual tetrabutyl ammonium dihydrogen phosphate remained behind, as judged by
NMR studies (see below), about 98% was removed by a single two-phase
partitioning.
Mass Spectrometry—Spectra of the purified donor lipid were acquired in the negative and positive linear modes using a time of flight
matrix-assisted laser desorption ionization (MALDI/TOF) mass spectrometer (Kompact MALDI 4, Kratos Analytical Manchester, UK),
equipped with a nitrogen laser (337 nm), 20-kV extraction voltage, and
time-delayed extraction. Each spectrum was the average of 50 laser
shots. The instrument was operated at a resolution of about ⫾1 atomic
mass units for compounds with Mr ⬃2000. Saturated 6-aza-2-thiothymine in 50% acetonitrile and 10% tribasic ammonium citrate (9:1, v/v)
served as the matrix in both the positive ion and the negative ion
modes. The lipid samples were dissolved in chloroform/methanol (4:1),
mixed 1:1 with the specified matrix, and dried at room temperature
prior to analysis.
NMR Spectroscopy—Approximately 0.2 mg of the purified donor lipid
was dissolved in 0.6 ml of CDCl3/CD3OD/D2O (2:3:1, v/v) in a 5-mm
NMR tube. NMR spectra were obtained at 25 °C using Varian Inova
800, Inova 600, or Unity 500 spectrometers, as indicated, equipped with
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FIG. 3. The presence of the putative L-Ara4N donor lipid is
regulated by the PmrA and PhoP/PhoQ systems of S. typhimurium. 32P-Labeled phospholipids from each strain of S. typhimurium were separated using the system chloroform/methanol/water/
NH4OH (65:25:3.6:0.4, v/v) and were visualized with a PhosphorImager.
Sun Ultra 10 computers and 5-mm Varian probes. The 2H signal of
CD3OD was used for a field frequency lock. Use of the CDCl3/CD3OD/
D2O solvent system introduces four solvent resonances. The signals
from CH3OD (3.3 ppm) and CHCl3 (7.6 ppm) do not overlap with the
donor lipid resonances. The HOD (4.6 ppm) and CD3OH (4.8 ppm)
signals are removed with a presaturation sequence.
1
H NMR spectra at 800 MHz were obtained with 8.2-kHz spectral
width, 73° pulse flip angle (7 s), 5.0 s acquisition time, and 1.2-s
relaxation delay. The spectra were digitized using 82,000 points yielding a digital resolution of 0.2 Hz/point. 1H NMR spectra at 600 MHz
were obtained with 5.7-kHz spectral width, 63° pulse flip angle (6 s),
5.6-s acquisition time, and 1.2-s relaxation delay and were digitized
using 64,000 points to give a digital resolution of 0.18 Hz/point. 1H
NMR spectra at 500 MHz were obtained with 4.5-kHz spectral width,
74° pulse flip angle (7.5 s), 5.0-s acquisition time, and 1.2-s relaxation
delay and were digitized using 45,000 points to obtain a digital resolution of 0.20 Hz/point. 31P NMR spectra at 202 MHz (500 MHz field) and
selective inverse (31P) decoupling difference spectra were obtained as
described previously (51–53). Two-dimensional-COSY, HMQC, and
HMBC analyses were performed at the 800- and 600-MHz fields, based
on the experiments described previously (51) at 500 MHz.
RESULTS

Isolation and Characterization of a Polymyxin-resistant Mutant of E. coli K-12—To facilitate the purification of the proposed undecaprenyl phosphate-L-Ara4N donor lipid, a new
polymyxin-resistant mutant of E. coli K-12, designated WD101,
was isolated by chemical mutagenesis of W3110. WD101
formed single colonies on agar containing 10 g/ml polymyxin.
The resistance phenotype was located near the pmrA/pmrB
locus at minute 93 on the E. coli chromosome (30), as judged by
P1vir transduction. Polymerase chain reaction-based cloning
and DNA sequencing of the pmrA/B cluster of WD101 showed

FIG. 4. Presence of the putative L-Ara4N donor lipid in a pmrAC mutant of E. coli lacking phosphatidylethanolamine. 32PLabeled phospholipids were isolated and separated by TLC using the
system chloroform/methanol/water/NH4OH (65:25:3.6:0.4, v/v) and
were visualized with a PhorphorImager.

that two amino acids were altered in the transcription factor
PmrA (A42T and G53E). No mutations were present in pmrB.
TLC analysis of 32P-labeled lipid A species isolated from
WD101 showed extensive modification with polar moieties,
when compared with wild-type W3110 (Fig. 2, left panel). The
modified lipid A components of WD101 were generally more
hydrophilic, indicating the presence of additional L-Ara4N
and/or pEtN substituents (26, 53), as judged by TLC analysis
(Fig. 2, left panel) and mass spectrometry (not shown). Lipid A
species containing an extra palmitoyl group were not detected
in large amounts in WD101, consistent with the activation of
pmrA but not phoP. These findings are in accord with earlier
studies (32) of polymyxin-resistant mutants of E. coli, which
were not characterized by DNA sequencing.
Accumulation of a Novel Minor 32P-Labeled Lipid in WD101
and in Certain Strains of S. typhimurium—The major phospholipids of WD101 consist of phosphatidylethanolamine,
phosphatidylglycerol, and cardiolipin, as in the wild-type
W3110 (Fig. 2, right panel). However, a minor 32P-labeled
substance, designated “L-Ara4N Donor,” accumulates in
WD101 to about 0.2– 0.4% of the total (Fig. 2, right panel).
The presence or absence of this putative L-Ara4N donor lipid
was further investigated using well characterized strains of S.
typhimurium containing mutations in the phoP/phoQ or pmrA/
pmrB systems (28, 29, 33, 54). As in WD101, the putative donor
lipid accumulates to the highest levels in S. typhimurium
strains in which PmrA is constitutively active (pmrAC) (Fig. 3,
lane 4). However, in contrast to E. coli W3110 (Fig. 2), the lipid
is also detectable in wild-type S. typhimurium (Fig. 3, lane 1).
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FIG. 5. Formation of pEtN-modified lipid A species requires
phosphatidylethanolamine in E. coli. The 32P-labeled lipid A species from the indicated strains were isolated as described under “Experimental Procedures,” separated by TLC using the solvent chloroform, pyridine, 88% formic acid, water (50:50:16:5, v/v), and visualized
with a PhosphorImager. A small amount of lipid A 4⬘-monophosphate
may arise as a decomposition product during pH 4.5 hydrolysis at
100 °C to remove the Kdo moiety.

This finding is consistent with the fact that lipid A of wild-type
S. typhimurium grown on LB broth contains some L-Ara4Nmodified species, albeit at lower levels than in pmrAC mutants
(26, 53).
The putative donor lipid was absent in a S. typhimurium
pmrA⫺ mutant (Fig. 3, lane 5) and was also missing in pmrAC
mutants containing deletions in either the pmrE or pmrF genes
(data not shown). The latter are required for the modification of
lipid A with the L-Ara4N moiety and for the maintenance of
polymyxin resistance (28). Furthermore, phoP/phoQ regulation
was evident in an otherwise wild-type background, given the
increase in the minor lipid in a PhoPC setting (Fig. 3, lane 2)
and its complete absence in a phoP⫺ mutant (Fig. 3, lane 3).
Because its presence or absence was regulated in the same
manner as reported previously for L-Ara4N addition to lipid A
in both E. coli (30, 32) and S. typhimurium (28, 29, 55), we
decided to purify and characterize the compound.
Construction a pmrAC E. coli Mutant (WD901) Lacking Phosphatidylethanolamine—Purification of the putative donor lipid
from WD101 or from a pmrAC mutant of S. typhimurium was
not feasible because it could not be separated from phosphatidylethanolamine, the major phospholipid of these bacteria (56),
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FIG. 6. Purification of the putative L-Ara4N donor lipid from a
pmrAC mutant of E. coli lacking phosphatidylethanolamine. The
lipids at each step of the purification were separated by TLC in the
system chloroform/methanol/water/NH4OH (65:25:3.6:0.4, v/v) and
were visualized by charring after spraying the plate with 10% sulfuric
acid in ethanol. Lane 1, unfractionated phospholipids of WD901 (pmrACpss⫺); lane 2, DEAE-cellulose column flow-through; lane 3, after C18
reverse phase chromatography; lane 4, after silicic acid chromatography; lane 5, after removal of the residual tetra-butyl dihydrogen ammonium phosphate by two-phase Bligh/Dyer partitioning.

in various large scale chromatography steps (data not shown).
To solve this problem, the pmrAC allele of WD101 was transferred into E. coli AD90/pDD72 (46) by P1vir transduction,
generating WD901/pDD72. After being cured of the covering
plasmid pDD72, these strains lack phosphatidylethanolamine
because of an insertion mutation in their chromosomal copy of
the pss gene. As shown in Fig. 4, lane 2, the presence of the
pmrAC mutation in WD901/pDD72 resulted in the accumulation of the putative L-Ara4N donor lipid. Once cured of pDD72,
the donor lipid was still produced by WD901, despite the complete absence of phosphatidylethanolamine (Fig. 4, lane 4).
Neither AD90/pDD72 nor AD90 contained this minor lipid (Fig.
4, lanes 1 and 3).
To make certain that the pss mutation had no effect on the
transfer of the L-Ara4N moiety to lipid A, 32P-labeled lipid A
species were prepared from AD90 (pss⫺) and WD901 (pss⫺
pmrAC) in the presence or absence of the pss⫹ covering plasmid
pDD72. As judged by TLC analysis, the pattern of lipid A
modifications of WD901/pDD72 (Fig. 5, lane 2) was identical to
that of WD101 (pss⫹pmrAC) (Fig. 2, left panel). Upon removal
of the pss⫹ covering plasmid pDD72, however, the three lipid A
species containing the pEtN moiety disappeared (Fig. 5, lane
4), whereas incorporation of the L-Ara4N moiety was unaffected. The lipid A species of AD90 grown with or without the
covering plasmid (Fig. 5, lanes 1 and 3) were essentially the
same as wild type (Fig. 2). These findings demonstrate that
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phosphatidylethanolamine is the source of the pEtN moieties
attached to lipid A in pmrAC mutants. About 70% of the lipid A
of WD901 consisted of a species with a single L-Ara4N substituent (Fig. 5, lane 4), presumably attached to the 4⬘-phosphate
position (52).
The relative resistance of AD90 and WD901 to polymyxin
could not be evaluated, because 50 mM Mg2⫹ (required for
growth of both strains) interfered with the disc diffusion assays
(data not shown).
Purification of the Putative L-Ara4N Donor Lipid from
WD901—A 100-mg sample of WD901 phospholipids (Fig. 6,
lane 1) was applied to a 20-ml DEAE-cellulose column equilibrated in chloroform/methanol/water (2:3:1, v/v). As expected,
phosphatidylglycerol and cardiolipin bound to the column,
whereas the putative donor lipid emerged in the run through
(Fig. 6, lane 2). This finding is consistent with the proposed
zwitterionic character of the donor lipid (Fig. 1). If pss⫹ cells
had been employed, phosphatidylethanolamine would also
have been present in the run through.
The DEAE-cellulose run-through fraction was applied to a
4.0-ml C18 reverse phase column, prepared in an acetonitrile/
water/isopropyl alcohol system containing tetra-butyl ammonium dihydrogen phosphate, and eluted with increasing
amounts of isopropyl alcohol (Fig. 6, lane 3). The final step was
chromatography on a 1-ml silicic column, yielding a homogenous preparation (Fig. 6, lane 4) as judged by TLC analysis.
The apparent Rf of the donor lipid increased slightly after the
reverse phase and silicic acid steps (Fig. 6, lanes 3 and 4),
possibly arising from interaction with contaminating tetrabutyl ammonium dihydrogen phosphate. When most of this
material was removed by two-phase Bligh/Dyer partitioning,
the purified lipid (⬃0.2 mg) migrated exactly like the desired
component of the original sample (Fig. 6, lane 5).
MALDI/TOF Mass Spectrometry of the Purified Lipid—
When analyzed in the negative mode, the purified material
yielded a major ion at m/z 977.5 (Fig. 7A), consistent with
[M-H]⫺ for the proposed structure (Fig. 1), undecaprenyl phosphate-L-Ara4N (Mr ⫽ 978.41). No peak was observed at m/z
1057.4 atomic mass units, the [M-H]⫺ expected for a hypothetical undecaprenyl diphosphate-L-Ara4N. Analysis of the purified sample in the positive ion mode produced a major peak at
m/z 767.9 atomic mass units, which could be interpreted as
arising from the fragment [undecaprenol ⫹ H]⫹ (Fig. 7B). The
molecular weight of undecaprenol is 767.3.
Characterization of the Purified Lipid by One-dimensional
1
H NMR Spectroscopy—The NMR spectra of the purified lipid
show all the features expected for a monoglycosylated polyisoprenyl phosphate (18, 19). The one-dimensional 800-MHz 1H
NMR spectra (Figs.8A to 10A, and Fig. 1 in the Supplemental
Material) reveal the following: 1) six resolved 1H resonances
between 5 and 3.2 ppm that can be assigned to the L-Ara4N
unit (Fig. 8A) (26, 57); 2) the CH (dd, 5.41 ppm) and the
proximal CH2OP (dd, 4.45 ppm) signals of the ␣ isoprene unit
(Figs. 1 and 8A) (18, 19); 3) the major unresolved CH resonances (⬃5.1 ppm) of the polyisoprene chain (Figs. 8A) (18, 19);
and 4) the major partially resolved CH2 (⬃2.1 ppm) and CH3
signals (1.6 –1.7 ppm) of the polyisoprene chain (Figs. 9B and
10B, and Fig. 1 in the Supplemental Material) (18, 19).
Mass spectrometry (Fig. 7) indicates the presence of 11 isoprene units in the purified donor lipid. Keeping in mind that
the  isoprene unit contains 2 methyl groups (one cis and one
trans in relation to the  methine proton), a total of 12 methyl
groups are expected (Fig. 1 and Table III). After correcting for
the overlap of the C-2 methylene proton signal arising from
residual tetra-butyl ammonium dihyrogen phosphate (designated ⫻ at the top of Figs. 9B and 10B), the 1H NMR signals

FIG. 7. MALDI/TOF mass spectrometry of the purified donor
lipid. The purified material was subjected to mass spectrometry in the
negative ion (A) or positive ion (B) modes. The molecular weights of
undecaprenyl phosphate-L-Ara4N, undecaprenyl phosphate, and undecaprenol are 978.41, 847.28, and 767.30, respectively.

between 1.6 and 1.75 ppm integrate to 12 methyl groups. The
methyl signal at 1.74 ppm (d, long range J ⫽ 1.0 Hz) (see Fig.
1 in the Supplemental Material) corresponds to the methyl
protons that are in cis configuration relative to the methine
proton of the ␣ isoprene residue (Figs. 1, 9B, and 10B). The
methyl signals at 1.70 and 1.69 ppm integrate to 6 and 2
methyl groups, respectively, corresponding to the 7 cis-methyls
of the interior isoprene units and the cis-methyl of the  isoprene unit (Figs. 1, 9B, and 10B and Table III). The methyl
signals at 1.63 and 1.61 ppm (Figs. 9B and 10B) integrate to 1
and 2 methyl groups, respectively, and are ascribed to the three
trans-methyls (as defined in relation to their respective methine protons) of the -2, -1, and  isoprene units (Fig. 1 and
Table III).
Characterization of the Purified Lipid by Two-dimensional
1
H NMR Spectroscopy—To our knowledge, intact samples of
undecaprenyl phosphate derivatives isolated from natural
sources have not been studied previously by two-dimensional
NMR methods because of their instability in the available
solvents (18, 19). However, as noted in our previous work (51)
with E. coli lipid A, many natural lipids, including undecaprenyl phosphate-L-Ara4N, are stable in CDCl3/CD3OD/D2O (2:
3:1, v/v) for weeks and display sharp, well resolved resonances.
The positions of the individual protons of the arabinose sugar
were derived from a two-dimensional COSY analysis (Fig. 8C,
Table II, and Fig. 1 in the Supplemental Material). The doubledoublet at 4.90 ppm (J1,2 ⫽ 6.4, JH1,P ⫽ 7.8 Hz) is assigned to
the anomeric H-1 proton of the L-Ara4N moiety (57). The COSY
cross-peak from H-1 (Fig. 8C) locates the H-2 signal at 3.61
ppm (dd, J1,2 ⫽ 6.4, J2,3 ⫽ 8.0 Hz). A second COSY cross-peak
from H-2 connects to H-3 at 3.81 ppm (dd, J2,3 ⫽ 8.0, J3,4 ⫽ 4.3
Hz) which, in turn, is coupled to H-4 at 3.29 ppm (broad
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FIG. 8. High resolution 1H NMR
spectra of the purified donor lipid. A,
the partial one-dimensional 800-MHz 1H
NMR spectrum of the donor lipid in
CDCl3/CD3OD/D2O (2:3:1, v/v) at 25 °C
shows the six resolved L-Ara4N protons
(H-1 through H-5⬘), the methine and proximal methylene protons of the ␣ isoprenyl
unit, and the bulk unresolved isoprenyl
methine protons. This spectrum was obtained using a presaturation sequence to
remove the HOD (4.8 ppm) and CD3OH
(4.5 ppm) resonances, giving a clear sugar
region. The large signal at 3.34 ppm (⫻)
arises from residual CD2HOD, and the
multiplet at 3.20 ppm (⫻) arises from the
C-1 methylene protons (the ones closest to
the N atom) of the butyl chains of residual
tetra-butyl ammonium dihydrogen phosphate carried over from the reverse phase
step of the purification. B, the selective
inverse decoupled difference 1H NMR
spectrum obtained at 500 MHz with on
and off resonance 31P decoupling of the
⫺0.44 ppm phosphorus signal shows that
the anomeric carbon of L-Ara4N is linked
via a phosphodiester to the proximal isoprene unit. C, the partial two-dimensional 1H–1H COSY analysis at 800 MHz
at 25 °C shows the connectivities between
the key sugar and isoprenyl 1H resonances seen in A.

multiplet). Further tracing of the COSY connectivities locate
the remaining L-Ara4N protons, i.e. H-5 (3.71 ppm; dd, J4,5 ⫽
2.4, J5⬘,5 ⫽ 12.8 Hz) and H-5⬘ (3.96 ppm; dd, J4,5⬘ ⫽ 4.1, J5,⬘5 ⫽
12.8 Hz).
The two-dimensional COSY also revealed a strong crosspeak between the CH and proximal CH2 groups of the ␣ isoprene unit (Fig. 8C). The CH and proximal CH2 of the ␣ isoprene unit each showed a weak cross-peak to the resolved
methyl signal at 1.74 ppm (see Fig. 1 in Supplemental Material). These weak cross-peaks arise from four- and five-bond long
range couplings and strengthen the assignment of the 1.74 ppm
methyl signal to the methyl group of the ␣ isoprene unit. The
major unresolved polyisoprene CH signals (⬃ 5.1 ppm) similarly show strong cross-peaks to the upfield CH2 resonances

and weaker (long range) cross-peaks to the upfield CH3 signals
(see Fig. 1 in the Supplemental Material).
The low field shift of H-1 (4.90 ppm) and the large J1,2
coupling constant (6.4 Hz) indicate that H-1 of the L-Ara4N
residue is in the axial position (57), so that the undecaprenyl
phosphate chain must be situated equatorially. The large J2,3
coupling (8 Hz) indicates that H-2 and H-3 are axially disposed
relative to each other. The intermediate J3,4 coupling (4.3 Hz)
indicates an axial-equatorial interaction, implying that H-4 is
equatorial and that the amino group is axial (as shown in Fig.
1). The measured values of 2.4 and 4.1 Hz for J4,5 and J4,5⬘ do
not allow distinction between the axial and equatorial H-5
protons. However, two-dimensional NOESY data (see Fig. 2 in
the Supplemental Material) revealed strong NOE cross-peaks
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FIG. 9. Partial HMQC spectra of the purified donor lipid. A, single bond 1H–13C correlations of the L-Ara4N moiety, part of the proximal
isoprene unit, and the unresolved olefinic protons of the undecaprenyl chain are shown. The noise streak at 4.56 ppm arises from the HOD signal.
Resonances designated ⫻ are due to residual solvents or other impurities. B, this expansion shows the partially resolved isoprenyl CH2 and CH3
groups and their directly bonded carbon atoms. The cis, trans, and adjacent configurations are defined in Table III. The butyl chains of tetra-butyl
ammonium dihydrogen phosphate, carried over from the reverse phase chromatography step of the purification, give rise to multiplet 1H
resonances at 3.20, 1.66, 1.44, and 1.04 ppm (see Supplemental Material Fig. 1). The tetra-butyl ammonium dihydrogen phosphate resonance (⫻)
at 1.66 ppm partially overlaps with two of the undecaprenyl CH3 signals of the donor lipid. The donor lipid sample used for the HMQC and HMBC
experiments also displayed CH3 (1.19 ppm) (not shown) and CH2 (3.63 ppm) signals arising from small amounts of an ethanol impurity in the
sample, which resulted in masking of the L-Ara4N H-2 by the ethanol CH2 signal in A. This impurity is not present in the experiment shown in
Fig. 8, in which an additional two-phase Bligh-Dyer partitioning was carried out to remove the contaminating ethanol.
TABLE II
H and 13C NMR assignments and coupling constants (J, Hz) of the L-Ara4N moiety in the purified donor lipid
1
H chemical shifts (ppm from internal TMS) are from one-dimensional 1H NMR spectra with a digital resolution of 0.2 Hz per point. Coupling
constants (JH,H, Hz) and (J1,P, Hz) were obtained from 31P-decoupled 1H NMR spectra. 13C chemical shifts (ppm from internal TMS) are estimated
from 2D HMQC spectra.
1

Ara4N

␦H

␦C

H-1
(J1,2)
(J1,P)

H-5
(J4,5)
(J5,5⬘)

H-5⬘
(J4,5⬘)
(J5,5⬘)

3.292

3.709
(2.4)
(12.8)

3.955
(4.1)
(12.8)

C-4
51.0

C-5
63.0

H-2
(J2,3)

H-3
(J3,4)

H-4

4.902
(6.4)
(7.8)

3.611
(8.1)

3.810
(4.3)

C-1
99.5

C-2
72.4

C-3
70.8

between H-1, H-3, and H-5, supporting the idea that these are
all axial protons on the same face (below plane in Fig. 1) of the
sugar. The equatorial H-4 (below plane) showed NOE crosspeaks to H-3 (axial, below plane) and to both H-5 protons but
with a stronger NOE cross-peak to H-5 (axial, below plane) and
a weaker NOE to H-5⬘ (equatorial, above plane) (see Fig. 2 in
the Supplemental Material). The large coupling (12.8 Hz) be-

tween H-5 and H-5⬘ (Table II) is typical of geminal methylene
protons within constrained pyranose rings (57).
Selective 31P-Decoupled 1H Difference Spectroscopy—The
linkage between the undecaprenyl chain and the arabinose
sugar unit was investigated. One-dimensional 31P NMR spectroscopy revealed a single phosphorus resonance near ⫺0.44
ppm, consistent with a phosphodiester linkage (see Fig. 3 in the
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Supplemental Material) (58). Next, subtraction of two 1H NMR
spectra obtained with on and off resonance selective decoupling
of the ⫺0.44 ppm phosphate signal (51, 52) revealed simultaneous decoupling changes at the anomeric H-1 signal of the
L-Ara4N moiety and at the proximal CH2 signal of the ␣ isoprene residue (Fig. 8B), thereby establishing the presence of a
single phosphate group linking the arabinose C-1 carbon and
the proximal CH2 carbon of the ␣ isoprene unit of the undecaprenyl chain (Fig. 1).
Evaluation of the Carbon Structure of the Donor Lipid by
HMQC Spectroscopy—To confirm the assignments derived
from the 1H NMR analysis, 13C data for the donor lipid (⬃0.2
mg) were obtained indirectly through 1H-detected HMQC and
HMBC two-dimensional NMR experiments. The partial twodimensional HMQC 1H-13C correlation map (Fig. 9A) reveals
six direct 1H-13C single-bond correlations in the sugar region
(Table II). The L-Ara4N H-1 signal reveals the anomeric carbon
resonance at 99.5 ppm (C-1). The H-5 and H-5⬘ multiplets
correlate to a single carbon signal at 63.0 ppm (C-5), whereas
the H-2 and H-3 multiplets connect to carbon resonances at
72.4 (C-2) and 70.8 (C-3) ppm, respectively, as predicted for
oxygen-substituted carbon atoms of sugars. However, nitrogensubstituted carbons of amino sugars resonate near 50 –55 ppm
(51, 59). The H-4 multiplet shows a prominent cross-peak near
51 ppm, confirming C-4 as the site of the amino group substitution. Fig. 9A also shows the direct bond correlations from the
major unresolved methine proton signals of the undecaprenyl
chain to unresolved olefinic carbon signals near 126 ppm, and
from the methine and the proximal methylene protons of the ␣
isoprene unit to carbon resonances at 122.8 and 63.5 ppm,
respectively.
The bulk CH2 protons of the undecaprenyl chain yield four
distinct 1H-13C HMQC cross-peaks (Fig. 9B and Table III).
Based upon the multibond correlations discussed below, the
major carbon peak at 27.2 ppm is assigned to the proximal CH2
groups of the bulk isoprene units (i.e. the ones adjacent to a
methine proton as shown in Table III), whereas the 33.0 ppm
peak of about equal intensity is assigned to those CH2 groups of
the bulk isoprene units that are trans relative to a methine
proton (Fig. 1 and Table III). The smaller carbon cross-peak at
40.5 ppm arises from the cis-CH2 groups of the -1 and -2
isoprene units (Fig. 1). The small cross-peak at 32.8 ppm arises
from the trans (distal) CH2 group of the ␣ isoprene unit (Fig. 1
and Table III).
The CH3 protons yield six distinct HMQC peaks (Fig. 9B).
The cis-CH3 protons of the ␣ isoprene unit (1.74 ppm), six of the
seven cis-CH3 protons of the interior ␤ to ⫺3 isoprene units
(1.70 ppm), and the remaining interior cis-CH3 group that
overlaps with the cis-CH3 of the  unit (1.69 ppm) yield distinct
carbon cross-peaks at 23.8, 24.1, and 26.3 ppm, respectively
(also see Table III). The three trans methyl groups of the -2,
-1, and  isoprene units yield three distinct carbon crosspeaks at 16.8, 16.8, and 18.2 ppm, respectively (Fig. 9B and
Table III).
Evaluation of the Carbon Structure of the Donor Lipid by
HMBC Spectroscopy—The HMBC multibond correlations in
the sugar region (Fig. 10A) verify the L-Ara4N assignments
derived from the COSY and HMQC experiments. For example,
H-5⬘ at 3.96 ppm shows distinct multibond correlations to C-4
(51.0 ppm), C-3 (70.8 ppm), and C-1 (99.5 ppm). The HMBC
correlations also yield a complete analysis of the ␣ isoprene
unit. The CH2OP proton signal at 4.44 ppm (also see Fig. 8A
and Table III) shows distinct multibond correlations to carbon
resonances at 122.8 ppm (the methine carbon of the ␣ isoprene
unit) and 142.0 ppm (the quaternary carbon of the ␣ isoprene
unit). The methine proton signal at 5.41 ppm yields multibond
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TABLE III
C and 1H NMR assignments (ppm from internal TMS) and coupling
constants (J, Hz) of the undecaprenyl chain in the donor lipid
The abbreviations used are: adj, adjacent in relation to a methine
proton of an isoprene unit; likewise, cis and trans are used throughout
to designate the configurations of various groups in relation to a methine proton of an isoprene unit, as shown above.
13

The abreviations used are: adj, adjacent in relation to a methine
proton of an isoprene unit; likewise, cis, and trans are used throughout
to designate the configurations of various groups in relation to a methine proton of a isoprene unit, as shown above.
** Proton-phosphorus coupling constant.

carbon peaks at 23.8 ppm (the cis-CH3 group of the ␣ isoprene
unit) and at 32.8 ppm (the distal trans CH2 of the ␣ isoprene
unit). Scrutiny of the cross-peaks from 1.74 ppm methyl proton
signal (Fig. 10B) shows the corresponding multibond correlations to 32.8, 122.8, and 142.0 ppm, thus verifying the assign-
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FIG. 10. Partial HMBC spectra of the purified donor lipid. A, the expansion shows multibond 1H–13C correlations from the L-Ara4N group
and the ␣ isoprenyl methine and proximal methylene unit. Noise streaks arise from HOD and ethanol signals at 4.56 and 3.6 ppm. The major HOD
signal has been suppressed with a presaturation pulse. The broad envelope signal at 4.53 ppm is a “probe-hump” artifact from a small residual
water magnetization being detected at an off resonance position by the leads of the probe coil. ⫻ indicates residual solvent or impurity resonances.
B, this expansion shows the region of the partially resolved bulk isoprenyl CH2 and CH3 groups. ⫻ indicates residual solvent or impurity
resonances.

ment of the 1.74 ppm signal as the cis-methyl group of the ␣
isoprene unit.
Similarly, the major unresolved CH proton signals (⬃5.1
ppm) of the undecaprenyl chain yield multibond correlations to
various CH3 and CH2 carbon resonances between 16 and 41
ppm (Fig. 10A). The major CH2 and CH3 proton signals show
multibond correlations to methine carbon peaks near 126 ppm
and to quaternary carbon signals near 136 ppm (Fig. 10B). The
trans-CH3 signals of the -1 and -2 units show a distinct
connectivity to the cis-CH2 carbons at 40 ppm, thus verifying
assignment of the upfield shifted CH2 proton signals (at 2.0
ppm) as cis-CH2 groups of the -1 and -2 units of the undecaprenyl chain. The interior ␤ to  ⫺3 cis-CH3 signals at 1.70
and 1.69 ppm show multibond correlations exclusively to the
CH2 carbons at 33.0 ppm, and not to the CH2 carbons at 27.0
ppm, thus yielding the assignment of the 33.0 ppm CH2 carbon
signals to the CH2 groups trans from the CH proton (Table III).
Finally, multibond correlations are seen in Fig. 10B from the
trans CH2 proton signals at 2.06 ppm to the adjacent CH2
carbon signals at 27.0 ppm, and from the adjacent CH2 proton
signals at 2.08 ppm to the trans CH2 carbon signals at 33.0
ppm. This cross-peak pattern is the reverse of that observed in
the direct correlation experiment (Fig. 9B).
The 1H and 13C NMR assignments derived for the sugar and

the undecaprenyl moieties of the donor lipid are summarized in
Tables II and III. The 13C NMR assignments derived for the 
to -2 units of the undecaprenyl chain are in excellent agreement with the 13C NMR assignments of farnesol, ␤-farnesene,
␤-springene, eleganediol, and other linear terpenes (60, 61).
Taken together with the coupling constants and the mass spectrometry, the results provide unequivocal proof for the novel
glycolipid structure proposed in Fig. 1, i.e. undecaprenyl
phosphate-␣-L-Ara4N.
Reconstitution of L-Ara4N Transferase Activity in Vitro with
Purified Undecaprenyl Phosphate-␣-L-Ara4N—Transfer of the
L-Ara4N moiety to lipid IVA to form lipid IIA proceeds rapidly
when ArnT is overexpressed in the polymyxin-resistant E. coli
host BLR(DE3) (Fig. 11) (25). However, when ArnT is overexpressed in the E. coli K-12 strain NovaBlue(DE3), transferase
activity is not observed (Fig. 11). Like all other E. coli K-12
strains, NovaBlue(DE3) does not synthesize the L-Ara4N donor
lipid (data not shown) and is sensitive to polymyxin (25). However, addition of purified undecaprenyl phosphate-␣-L-Ara4N
to membranes of E. coli K-12 NovaBlue(DE3) cells overexpressing arnT reconstitutes robust lipid IIA formation in vitro in a
concentration-dependent manner, whereas donor lipid addition
to membranes from the vector control cells NovaBlue(DE3)/
pET21 does not (Fig. 11). Efficient reconstitution was also seen
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FIG. 11. Reconstitution in vitro of
ArnT activity with purified undecaprenyl phosphate-␣-L-Ara4N. ArnT
was assayed using 10 M [4⬘-32P]lipid IVA
as the acceptor substrate under standard
assay conditions for 5 min with 0.5 mg/ml
of membrane protein, except that the Triton X-100 concentration was increased to
0.7% to dissolve the undecaprenyl phosphate-␣-L-Ara4N. The source of the membranes, as indicated, was from the polymyxin-resistant BLR(DE3)/pLysS or the
polymyxin-sensitive NovaBlue(DE3)/
pLysS E. coli host strains, containing either the pET21 vector or the hybrid pArnTEc plasmid (25). The purified donor
substrate was added in increasing concentrations ranging from about 1.5 to 150 M.
In the left panel, 150 M donor was included in the indicated reaction. The products were separated by TLC using the solvent chloroform, pyridine, 88% formic acid,
water (50:50:16:5, v/v) and were detected
with a PhosphorImager.

when using membranes of E. coli K-12 NovaBlue(DE3) overexpressing S. typhimurium arnT (data not shown). ArnT activity,
which was absent in a pmrE⫺ or pmrF⫺ derivative of a pmrAC
mutant of S. typhimurium, was likewise recovered by the addition of purified donor lipid to membranes (data not shown).
These findings, in conjunction with product analysis presented
in the accompanying article (25), demonstrate conclusively that
the addition of the L-Ara4N moiety to lipid A requires undecaprenyl phosphate-␣-L-Ara4N as the donor substrate.
DISCUSSION

The lipid A moiety of lipopolysaccharide of certain Gramnegative bacteria can be modified with the positively charged
sugar L-Ara4N (58, 62– 66) in a regulated manner (26, 28, 55).
By masking of the negative phosphate groups of lipid A, the
L-Ara4N residue prevents binding of cationic antimicrobial
peptides and polymyxin to the outer membrane, rendering the
bacteria resistant to killing by these substances (30 –32, 37). In
the intracellular pathogen S. typhimurium, modification with
the L-Ara4N unit may occur on both the 1- and the 4⬘-phosphate groups of lipid A (53, 58). Modification of the 4⬘-position
is predominant under most conditions (52, 53) but appears to
be Kdo-dependent.
As was suggested by our bioinformatic analysis of the pmrF
operon (26), a polyisoprene-linked intermediate is required for
the transfer of the L-Ara4N moiety to lipid A. Here we have
presented the identification, purification, and biophysical characterization of this novel substance, which is now properly
described as undecaprenyl phosphate-␣-L-Ara4N or undecaprenyl 4-amino-4-deoxy-␣-L-arabinopyranosyl phosphate. This
material was first detected as a minor phospholipid that accumulates in a polymyxin-resistant mutant of E. coli (Fig. 2). In
S. typhimurium, the lipid is also present in wild-type cells, but
its level is increased in pmrAC and PhoPC mutants. It is absent
in pmrA⫺ strains (Fig. 3).
The purification to near-homogeneity of the donor lipid required as a first step the construction of a special pmrAC
mutant of E. coli lacking phosphatidylethanolamine to simplify
all subsequent procedures (Figs. 4 – 6). MALDI/TOF mass spectrometry and high resolution NMR spectroscopy were then
used for the actual structure determination. As noted in previous NMR studies of lipid A, the mixture CDCl3/CDOD/D2O
(2:3:1, v/v) is ideal for NMR analyses of small lipid samples (51,

52, 67), because there is no measurable decomposition for
weeks under these conditions. The data (shown in Figs. 7–10,
Tables II and III, and see Figs. 1–3 in the Supplemental Material) confirm unequivocally that the L-Ara4N donor substrate
has the structure undecaprenyl phosphate-␣-L-Ara4N. The proposed structure and conformation of the sugar is supported by
its coupling constants and chemical shifts, summarized in Table II, which are in accord with a synthetic standard of L-Ara4N
(57). The attachment of the nitrogen atom to position 4 of the
sugar is established by the HMQC experiment (Fig. 9A). The
size and configuration of the polyisoprene chain are confirmed
by mass spectrometry (Fig. 7) and by the HMQC/HMBC analyses (Figs. 9 and 10).
Reconstitution of the purified lipid donor with the cloned E.
coli or S. typhimurium L-Ara4N transferase (ArnT) resulted in
robust in vitro conversion of the precursor lipid-IVA to lipid-IIA
(Fig. 11), a compound that contains a single L-Ara4N moiety on
its 1-phosphate residue (50, 52, 58). ArnT is a complex enzyme
with 12 predicted trans-membrane helices (25) and is a member of an ancient family of glycosyltransferases that includes
the eucaryotic protein mannosyltransferases (23, 68). All the
enzymes of this family appear to use polyisoprene-linked
sugars as their donor substrates (23, 68). However, prior to
the present work, identification of undecaprenyl phosphate␣-L-Ara4N and in vitro systems for detecting the transfer of
L-Ara4N to lipid A or lipid A precursors had not been
reported.
Many interesting questions regarding the possible translocation of the donor lipid across the inner membrane for utilization by ArnT in the periplasm remain unanswered. The
relevant transporter has not been identified. It is unlikely that
Wzx (RfbX), the putative O-antigen flippase (5, 69), is responsible for the translocation of undecaprenyl phosphate-␣-LAra4N into the periplasm, because Wzx proteins are thought to
transport undecaprenyl diphosphate oligosaccharides (70).
Nevertheless, wzx-deficient mutants should be tested for their
sensitivity to polymyxin. Most importantly, perhaps, in vitro
systems for measuring flip-flop of undecaprenyl phosphate-␣L-Ara4N across lipid bilayers need to be developed, but first,
efficient enzymatic, radiochemical, and chemical methods for
making undecaprenyl phosphate-␣-L-Ara4N must be devised. A
new enzymatic system for the conversion of UDP-glucuronic
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acid to UDP-L-Ara4N has recently been identified in extracts of
polymyxin-resistant mutants of E. coli,3 and should facilitate
the preparation of undecaprenyl phosphate-␣-L-Ara4N.
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64. Galanos, C., Rietschel, E. T., Lüderitz, O., and Westphal, O. (1977) in International Review of Biochemistry: Biochemistry of Lipids II (Goodwin, T. W.,
ed) Vol. 14, pp. 239 –335, University Park Press, Baltimore
65. Sidorczyk, Z., Zahringer, U., and Rietschel, E. T. (1983) Eur. J. Biochem. 137,
15–22
66. Boll, M., Radziejewska-Lebrecht, J., Warth, C., Krajewska-Pietrasik, D., and
Mayer, H. (1994) FEMS Immunol. Med. Microbiol. 8, 329 –341
67. Que, N. L. S., Ribeiro, A. A., and Raetz, C. R. H. (2000) J. Biol. Chem. 275,
28017–28027
68. Dotson, S. B., Rush, J. S., Ricketts, A. D., and Waechter, C. J. (1995) Arch.
Biochem. Biophys. 316, 773–779
69. Liu, D., Cole, R. A., and Reeves, P. R. (1996) J. Bacteriol. 178, 2102–2107
70. Feldman, M. F., Marolda, C. L., Monteiro, M. A., Perry, M. B., Parodi, A. J.,
and Valvano, M. A. (1999) J. Biol. Chem. 274, 35129 –35138
71. Miller, S. I., and Mekalanos, J. J. (1990) J. Bacteriol. 172, 2485–2490
72. Gunn, J. S., Belden, W. J., and Miller, S. I. (1998) Microb. Pathog. 25, 77–90

